Get the Stockscreener App
164.40
0.88%
1.44
Pre-market:
166.00
1.60
+0.97%
Illumina Inc stock is traded at $164.40, with a volume of 2.19M.
It is up +0.88% in the last 24 hours and up +21.08% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$162.96
Open:
$160.85
24h Volume:
2.19M
Relative Volume:
1.33
Market Cap:
$24.87B
Revenue:
$4.39B
Net Income/Loss:
$853.00M
P/E Ratio:
29.84
EPS:
5.5097
Net Cash Flow:
$556.00M
1W Performance:
+13.84%
1M Performance:
+21.08%
6M Performance:
+27.72%
1Y Performance:
+99.90%
1-Day Range:
$160.84
$165.97
1-Week Range:
$142.61
$165.97
52-Week Range:
$78.79
$165.97
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
164.40 | 24.66B | 4.39B | 853.00M | 556.00M | 5.5097 |
TMO
Thermo Fisher Scientific Inc
|
494.04 | 183.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
179.87 | 129.29B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
566.79 | 44.45B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.98 | 38.25B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
378.16 | 37.66B | 3.77B | 449.25M | 240.68M | 7.8556 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Why (ILMN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Corvex funds tied to Illumina (ILMN) log 669,596-share stock sale - Stock Titan
Illumina (ILMN) legal chief sells 615 shares in open market trade - Stock Titan
Illumina Inc. stock (US4523271090): New oncology research workflows and MRD solution highlight innov - AD HOC NEWS
Illumina (ILMN) chief accounting officer sells 2,000 company shares in open market - Stock Titan
Hunting for hidden clues in the human genome’s “dark regions” - Illumina
Integrated DNA Technologies (DHR) Partners with Illumina for Enh - GuruFocus
IDT partners with Illumina on oncology research workflow - Investing.com
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights - Eagle-Tribune
Integrated DNA Technologies and Illumina, Inc. Announce Strategic Collaboration for End-to-End Oncology Research Workflows Optimized on Illumina Software - marketscreener.com
Guggenheim Maintains Illumina(ILMN.US) With Buy Rating, Raises Target Price to $180 - Moomoo
Guggenheim raises Illumina stock price target on clinical market strength - Investing.com
Illumina, Inc. (ILMN) Stock Analysis: Understanding the Growth Potential Amidst a Robust Market Cap - DirectorsTalk Interviews
Illumina Inc. stock (US4523271090): shares track Nasdaq ahead of next catalysts - AD HOC NEWS
Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains - Yahoo Finance Singapore
Illumina Inc. stock (US4523271090): insider share sale and new MRD kit draw investor focus - AD HOC NEWS
Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360
Corvex Management LP sells multiple ILMN blocks (ILMN) in May 2026 - Stock Titan
Illumina, Inc. Hits New 52-Week High of $158.78, Up 48.7% - Markets Mojo
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
lllumina Beats Rival’s DNA-Sequencing Tool Monopolization Claims - news.bloombergtax.com
Illumina, Inc. Hits Day High with Strong 5.68% Intraday Surge - Markets Mojo
Illumina (NASDAQ: ILMN) director sold 1,500 shares under 10b5-1 plan - Stock Titan
[144] ILLUMINA, INC. SEC Filing - Stock Titan
Illumina (ILMN) director Keith Meister updates 3.5M indirect share position - Stock Titan
Illumina Inc. stock (US4523271090): shares near 12-month high after new automation launch - AD HOC NEWS
Illumina launches new sequencing tech for molecular residual disease research - MSN
Illumina and SPT Labtech on fire with new collaboration - Business Weekly
Assessing Illumina (ILMN) Valuation After Its New MRD Research Solution Expands Oncology Offering - Sahm
Illumina Inc stock (US4523271090): New MRD research launch and fresh 52-week high draw focus to valu - AD HOC NEWS
Illumina stock hits 52-week high at 155.6 USD By Investing.com - Investing.com Nigeria
Frances Arnold proposes sale of 5,000 ILMN shares (ILMN) - Stock Titan
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - Illumina
Illumina's new fireflyGO robot targets faster cancer lab workflows - Stock Titan
Illumina, Inc. Introduces Distributed Whole-Genome Sequencing Solution For Highly Sensitive MRD Research - marketscreener.com
Illumina stock hits 52-week high at 155.6 USD - Investing.com
Illumina launches whole-genome sequencing kit for cancer research By Investing.com - Investing.com Australia
Illumina launches whole-genome sequencing kit for cancer research - Investing.com
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research - PR Newswire
Is Illumina Inc (ILMN) Overvalued After 3.4% Rally? GF Value Say - GuruFocus
Illumina, Inc. Files Form 8-K Announcing Annual Meeting Results and Company Information (May 2026) - Minichart
Illumina (ILMN) shareholders back board slate, auditor and pay at 2026 meeting - Stock Titan
Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Action challenging Commission’s jurisdiction over Grail’s acquisition of Illumina, published in OJ - EU Law Live
Illumina Multiomics Summit India highlights potential of integrated omics - BioSpectrum India
Illumina Inc. stock (US4523271090): Focus shifts to core sequencing business after divesting GRAIL - AD HOC NEWS
How Adding Diagnostics Veteran David King To The Board At Illumina (ILMN) Has Changed Its Investment Story - simplywall.st
Illumina, Inc. (ILMN) Stock Analysis: Navigating the Genetic Sequencing Giant’s Potential with a 33.82% ROE - DirectorsTalk Interviews
ILMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Illumina stock (US4523271090): institutional buying meets cautious analyst outlook - AD HOC NEWS
Illumina Summit Highlights Multi-Omics Potential in India - Deccan Chronicle
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):